Related Experiment Video
Updated: Jul 13, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Primary diffuse large B-cell lymphoma of the breast
Hajime Kuroda1, Jun-ichi Tamaru, Ikuya Takeuchi
1Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan.
Breast Cancer (Tokyo, Japan)
|August 11, 2007
Summary
Diffuse large B cell lymphoma (DLBL) is a rare breast cancer. This study highlights that BOB.1 and Oct2 are useful immunohistochemical markers for diagnosing DLBL of the breast.
Area of Science:
- Oncology
- Pathology
Background:
- Diffuse large B cell lymphoma (DLBL) is a rare breast malignancy.
- Diagnosis relies on cytological and histopathological features, which can be challenging.
Observation:
- A 28-year-old woman presented with a breast mass initially diagnosed as malignant tumor not otherwise specified.
- Fine-needle aspiration cytology and excisional biopsy suggested malignant lymphoma, but distinguishing it from reactive lymphocytes was difficult.
Findings:
- Histological diagnosis confirmed DLBL of the breast.
- Immunohistochemical staining for CD20, CD79a, BOB.1, and Oct2 in atypical lymphocytes was strongly positive.
- BOB.1 and Oct2, alongside pan-B-cell markers, aid in DLBL diagnosis.
Implications:
- Accurate immunohistochemical markers are crucial for diagnosing rare breast tumors like DLBL.
- The study supports the utility of BOB.1 and Oct2 as diagnostic markers for breast DLBL.
- Improved diagnostic accuracy can lead to timely and appropriate patient management.
